Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Rachel Ellingson joined the board in April 2021. Since April 2018, Ms. Ellingson has served as senior vice president and chief strategy officer at Zimmer Biomet Holdings, Inc., a medical device company (NYSE: ZBH). The Board has determined that Ms. Ellingson is qualified to serve on the Board because of her strategic leadership experience. |
| 2022-04-29 | Rachel Ellingson has served as a director and member of the Company’s Compensation Committee and Audit Committee since April 2021. The Board has determined that Ms. Ellingson is qualified to serve as a director because of her experience with strategic leadership and investment banking. The following table sets forth the current composition of the three standing committees of our Board: Ms. Ellingson - Audit Committee member, Compensation Committee member, Governance and Nominating Committee member. The following table sets forth a summary of the compensation the Company paid to its non-employee directors in the year ended December 31, 2021. Rachel Ellingson total compensation for 2021 was $215,250. |
| 2023-06-06 | Rachel Ellingson 53 Director The following table sets forth information regarding compensation earned by our non-employee directors for the year ended December 31, 2022. Rachel Ellingson 50,000 - 50,000 The following table sets forth a summary of the compensation the Company paid to its non-employee directors in the year ended December 31, 2022. Rachel Ellingson 40,833 194,144 234,977 |
| 2024-06-05 | Rachel Ellingson has served as a director and member of the Company’s Compensation Committee and Audit Committee since April 2021. |
Data sourced from SEC filings. Last updated: 2026-02-03